Publication date: Mar 14, 2019
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first clinical study with ABBV-0805 has started in the U. S. AbbVie is responsible for the clinical development of ABBV-0805.
ABBV-0805 is a result of a strategic research alliance between BioArctic and AbbVie focused on the development of a potential immunotherapy for Parkinson’s disease.
- AbbVie on go to start clinical development of Parkinson’s candidate ABBV-0805
- AbbVie, Voyager Team Up to Develop Antibodies for Parkinson’s, Other Diseases
- Axovant Reports Positive Interim Results From First Cohort Of SUNRISE-PD Phase 2 Trial Of AXO-Lenti-PD Gene Therapy In Parkinson’s Disease
- Trial Offers Hope For Restoring Brain Cells Damaged In Parkinson’s